ArticleAmerican journal of cancer research2026
USP5 promotes glycolysis in cervical cancer by stabilizing FOXM1.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer treatment faces challenges like limited efficacy, side effects, and high costs. Hence, unearthing feasible objectives targeting pathogeny is compulsory for the management of cervical cancer. Ubiquitin-specific peptidase 5 (USP5) acts as an oncogene in various cancers, but its role in cervical cancer continues vague. USP5 expression was assessed bioinformatically and experimentally. Studies involving gain and loss of function were performed in Hela and CaSki cells as well as in a xenograft mouse model. Assays included reverse transcription-quantitative polymerase chain reaction (RT-qPCR), cell counting kit-8 (CCK-8), clonogenesis, flow cytometry, western blot, co-immunoprecipitation (Co-IP), and immunohistochemistry. High USP5 expression predicted poor prognosis in cervical cancer patients. USP5 knockdown inhibited cell proliferation, glycolysis (reducing GLUT1, PGC-1α, HK, LDHA expression, glucose uptake, and lactate production), and induced apoptosis, while overexpression had opposite effects. USP5 stabilized FOXM1 via deubiquitination, which was crucial for USP5-mediated oncogenic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.